Authors’ Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?

Detalles Bibliográficos
Autores principales: Gomes, Luis Eduardo Miani, da Silva, Francesca Aparecida Ramos, Pascoal, Lívia Bitencourt, Ricci, Renato Lazarin, Nogueira, Guilherme, Camargo, Michel Gardere, de Lourdes Setsuko Ayrizono, Maria, Fagundes, João José, Leal, Raquel Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2019
Materias:
Comments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751365/
https://www.ncbi.nlm.nih.gov/pubmed/31576921
http://dx.doi.org/10.6061/clinics/2019/e1517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751365/
https://www.ncbi.nlm.nih.gov/pubmed/31576921
http://dx.doi.org/10.6061/clinics/2019/e1517

Ejemplares similares